Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview.

Chloride channel potentiator and corrector elexacaftor/tezacaftor/ivacaftor (ETI) has reduced the burden of disease in people with cystic fibrosis (PwCF) and led to some patients ceasing high-burden treatment regimens. This study was a prospective survey and qualitative interview that evaluated medications PwCF had ceased after ETI. It demonstrated that a majority of PwCF have ceased medications, which prompts further research to rationalise medication regimens for PwCF.